Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00683852 · ClinicalTrials.gov registry record · Phase 3
A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
NCT00683852: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00683852 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 225 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00683852, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
Primary Outcome
The primary outcome was the difference in response rate (decrease in MADRS total score of at least 50%) using the SPCD (sequential parallel comparison design). The 10-item Montgomery-Asberg Depression Rating Scale (MADRS), which measures depression severity over the past week, was completed by clinicians using an MGH structured interview. Each item is measured on a scale from 0 to 6, and the items are summed to find the total score. The total minimum score is 0 units on a scale and the total max
Interventions
- DRUG Placebo
- DRUG Aripiprazole 5mg
- DRUG Aripiprazole 2mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 3 |
What the finished NCT00683852 record still lists
NCT00683852 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00683852 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00683852 about?
NCT00683852 is a clinical study titled "A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy". The purpose of this study is to determine whether a reduced dose of aripiprazole is effective in treating patients with major depressive disorder
What is the current status of trial NCT00683852?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2008-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00683852?
The interventions under investigation include: Placebo (DRUG), Aripiprazole 5mg (DRUG), Aripiprazole 2mg (DRUG).
Who is sponsoring clinical trial NCT00683852?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00683852's enrollment target sits among peer trials
225 1311th of 2000 higher than 684 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia